


PHILIPS

AngioSculpt Evo


PTCA scoring
balloon catheter




AngioSculpt Evo

Maximize gain. Minimize risk.

- AngioSculpt Evo has the power to safely dilate resistant lesions^{1,2,3}
- Delivers up to 25X the force of conventional balloons⁴
- Provides the largest effective scoring area of any specialty balloon⁴
- AngioSculpt Evo is 43% smaller and 44% more deliverable than Wolverine¹
- AngioSculpt Evo is indicated for use in the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis (ISR) and complex type C lesions^{5,6}



Scoreflex⁷
2 Guidewires
Longitudinal scoring



AngioSculpt Evo
Helical scoring elements
Circumferential scoring



Wolverine⁸
3-4 Atherotomes
Longitudinal cutting

Advantages of Circumferential Scoring

Precision: AngioSculpt Evo modifies plaque in a controlled manner for uniform scoring⁴

Power: The nitinol scoring element wraps the entire balloon to concentrate focal forces up to 25x the force of conventional balloons⁴

Safety: Reduced risk of dissection – A U.S. pivotal study reported only 1% Type D-F flow-limiting dissections post-AngioSculpt, underscoring its safety^{4,5}

*Based on AngioSculpt PTCA clinical data

AngioSculpt Evo scoring balloon compared with Wolverine cutting balloon

Indications for use

- In-stent restenosis (ISR)
- ACC/AHA lesion specific classification Type B2 and C
 - Total occlusions – traversable by guidewire
 - Moderately and severely calcified
 - Eccentric lesions
 - Ostial lesions
 - Long lesions > 20 mm diffuse disease

AngioSculpt Evo ^{5,6}	Wolverine ⁹
✓	✗
✓	✗
✓	✗
✓	✗
✓	✗
✓	✗
✓	✗

AngioSculpt Evo ordering information

Number	Balloon diameter (mm)	Balloon length (mm)	Catheter length	Guidewire compatibility	Guide catheter compatibility
2200-2006-B	2.0	6	139	0.014"	5Fr
2200-2010-B	2.0	10	139	0.014"	5Fr
2200-2015-B	2.0	15	139	0.014"	5Fr
2200-2020-B	2.0	20	139	0.014"	5Fr
2200-2506-B	2.5	6	139	0.014"	5Fr
2200-2510-B	2.5	10	139	0.014"	5Fr
2200-2515-B	2.5	15	139	0.014"	5Fr
2200-2520-B	2.5	20	139	0.014"	5Fr
2200-3006-B	3.0	6	139	0.014"	5Fr
2200-3010-B	3.0	10	139	0.014"	5Fr
2200-3015-B	3.0	15	139	0.014"	5Fr
2200-3020-B	3.0	20	139	0.014"	5Fr
2200-3506-B	3.5	6	139	0.014"	5Fr
2200-3510-B	3.5	10	139	0.014"	5Fr
2200-3515-B	3.5	15	139	0.014"	5Fr
2200-3520-B	3.5	20	139	0.014"	5Fr

AngioSculpt Evo PTCA important safety information

The AngioSculpt Evo Scoring Balloon Catheter is indicated for use in the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion. The AngioSculpt Evo catheter should not be used for coronary artery lesions unsuitable for treatment by percutaneous revascularization, and coronary artery spasm in the absence of a significant stenosis. Possible adverse effects include, but are not limited to: death; heart attack (acute myocardial infarction); embolism, total occlusion of the treated coronary artery; coronary artery dissection, perforation, rupture, or injury; pericardial tamponade; no/slow reflow of treated vessel; emergency coronary artery bypass (CABG); emergency percutaneous coronary intervention; CVA/stroke/embolic stroke; pseudoaneurysm; restenosis of the dilated vessel; unstable angina; thromboembolism or retained device components; irregular heart rhythm (arrhythmias, including life-threatening ventricular arrhythmias); severe low (hypotension)/high (hypertension) blood pressure; coronary artery spasm; hemorrhage or hematoma; need for blood transfusion; surgical repair of vascular access site; creation of a pathway for blood flow between the artery and the vein in the groin (arteriovenous fistula); drug reactions, allergic reactions to x-ray dye (contrast medium); and infection. This information is not intended to replace a discussion with your healthcare provider on the benefits and risks of this procedure to you. Caution: Federal law restricts this device to sale by or on the order of a physician.

References

1. D051336 AngioSculpt Evo Marketing Claims Report.
2. Costa JR, Mintz GS, Carlier SG, et al. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. *Am J Cardiol.* 2007;100:812-817.
3. Costa RA, Mooney MR, Teirstein PS, et al. Final results from the multi-center trial of the angiosculpt scoring balloon catheter for the treatment of complex coronary artery lesions. *Cardiovascular Revascularization Medicine* 7 (2006)81-126.
4. Data on file, SR-1571.
5. AngioSculpt Evo IFU P015608-B.
6. Data on file at Philips IGT: D050055_Clinical Evaluation Report AngioSculpt EVO and PTCA Scoring Balloon Catheter.
7. Abbott. (n.d.). Scoreflex NC scoring balloon. Retrieved May 16, 2025, from <https://www.cardiovascular.abbott/us/en/hcp/products/percutaneous-coronary-intervention/coronary-dilatation-catheters/scoreflex-nc-scoring-balloon.html>
8. Boston Scientific. (n.d.). Wolverine coronary cutting balloon. Boston Scientific. Retrieved March 12, 2025, from <https://www.bostonscientific.com/us/en/healthcare-professionals/products/balloons-catheters-and-guidewires/cutting-balloons/wolverine-coronary-cutting-balloon/fp00000353.html>
9. WOLVERINE™ Coronary Cutting Balloon. Boston Scientific. (n.d.). Indications, safety, and warnings. Boston Scientific. Retrieved May 15, 2025, from <https://www.bostonscientific.com/us/en/healthcare-professionals/products/balloons-catheters-and-guidewires/cutting-balloons/wolverine-coronary-cutting-balloon/fp00000353/indications-safety-and-warnings.html>